Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
The ASCO Annual Meeting closed June 2 after a week that moved peptide and targeted-conjugate oncology from abstract to podium: Bicycle's bicyclic peptide-drug conjugate and Avacta's FAP-activated conjugate in solid tumors, Mayo's folate-receptor and BioVaxys' survivin peptide vaccines, Sapience's C/EBPβ antagonist in glioblastoma, and PSMA and lead-212 radioligands from Telix and Perspective. Attention now shifts to ADA 2026 in New Orleans and the July 23-24 PCAC compounding vote.
Eli Lilly will present full data on retatrutide, Foundayo (orforglipron), and Mounjaro at the American Diabetes Association's 86th Scientific Sessions. The triple agonist retatrutide lowered A1C by up to 2.0% and drove 16.8% weight loss, about 36.6 lbs at the 12 mg dose, over 40 weeks in its first Phase 3 diabetes trial, TRANSCEND-T2D-1. Oral Foundayo beat oral semaglutide head-to-head with 73.6% greater relative weight loss and an A1C reduction of up to 1.7% against 0.8% for dapagliflozin.
Syneron Bio, a Beijing-based macrocyclic peptide drug discovery company, closed a $150 million Series B led by an international life-science fund with co-leads Decheng Capital and CDH VGC, roughly four months after a $100 million Series A. Investors include a subsidiary of the Abu Dhabi Investment Authority, Qiming Venture Partners, and existing shareholder AstraZeneca, whose 2025 platform partnership carried $75 million upfront and near-term payments plus up to $3.4 billion in milestones. The raise reflects continued investor appetite for macrocyclic and oral peptide platforms, alongside Pinnacle Medicines' $89 million round.
BriaCell Therapeutics priced a registered direct offering of 1,449,300 common shares at $3.25 each for gross proceeds of about $4.7 million, with ThinkEquity as sole placement agent. The company plans to use proceeds for working capital, general corporate purposes, and advancing its pipeline. The raise lands days after BriaCell reported 16.6-month median overall survival for its Bria-IMT cell-based immunotherapy in heavily pretreated metastatic breast cancer at ASCO 2026.
ASCO's Sunday education and poster sessions in Chicago set up the meeting's densest peptide-oncology day on Monday, June 1, when Bicycle Therapeutics presents Duravelo-2 (zelenectide pevedotin in first-line urothelial cancer, Abstract 4516), Mayo Clinic presents the TPIV200 folate-receptor-alpha vaccine in triple-negative breast cancer (Abstract 536), and Telix presents ProstACT Global PSMA radioligand data. Corbus CRB-701 and BioVaxys MVP-S round out the targeted-conjugate and vaccine slate.
The copper-peptide (GHK-Cu, copper tripeptide-1) cosmetic category continued its 2026 surge through late May. Neurogan Health's 2% GHK-Cu body-care line documented a 32.8% reduction in wrinkle depth and 20-30% improvement in skin firmness in 12-week clinical testing. Auro Wellness, founded by peptide-delivery specialist Nayan Patel, anchors its copper-tripeptide serum on a proprietary delivery system. GHK-Cu is the fastest-growing peptide search term of 2026, with consumer interest spanning skin rejuvenation, hair loss, and systemic longevity. GHK-Cu activates over 4,000 human genes involved in collagen synthesis, anti-inflammation, and tissue remodeling. The cosmetic surge runs in parallel with the FDA's regulatory cycle: injectable GHK-Cu is on the docket for the February 2027 PCAC meeting alongside Melanotan II, LL-37, Dihexa, and PEG-MGF, while the topical cosmetic form remains in the lighter-regulated personal-care channel. The category illustrates the consumer end of the peptide landscape maturing alongside the therapeutic pipeline.
ASCO 2026 Day 2 in Chicago continued the meeting's peptide-and-targeted-conjugate oncology programming. Saturday May 30 brought the Immutep eftilagimod alfa survival pooled analysis and the ImPact Biotech padeliporfin VTP pancreatic data, alongside the Bicycle Therapeutics zelenectide pevedotin dose-optimization poster (Abstract 4567, May 31) approaching. The meeting's heaviest peptide-mechanism day is Monday June 1: Bicycle Duravelo-2 zelenectide pevedotin + pembrolizumab oral presentation in 1L urothelial (Abstract 4516, 8:30 AM CT); Mayo Clinic TPIV200 folate-receptor peptide vaccine in triple-negative breast cancer (Abstract 536, 1:30 PM CT); Telix ProstACT PSMA radioligand Phase 3 Part 1; Sapience lucicebtide GBM poster. The Corbus CRB-701 Nectin-4 ADC data (42.9% OPSCC / 34.4% cervical) landed Friday May 29. The targeted-conjugate categories — Nectin-4, PSMA, B7-H3, FAP, SSTR2 — remain the densest peptide-adjacent oncology competition, with the bulk of definitive readouts concentrated in the meeting's back half through June 2.
EASL 2026 closed in Barcelona on May 30 after a week that reshaped two liver-disease narratives. On MASH: the GLP-1/glucagon peptide cohort (survodutide NEJM 47-62% MASH improvement, pemvidutide Best of EASL with cardiometabolic and fibrosis data, MetaVia DA-1726 9.1% weight loss) competed against THR-β agonism (Madrigal Rezdiffra, Aligos ALG-055009 46% liver fat), RNAi (Arrowhead ARO-INHBE), and FGF21 analogs (the Akero and 89bio programs that drew $5.2B and $3.5B acquisitions). On HBV/HDV: the entry-inhibitor peptides (Gilead's newly approved bulevirtide, Assembly's oral ABI-6250) shared the stage with gene editing (Precision PBGENE-HBV cccDNA elimination), epigenetic silencing (TUNE-401), capsid modulation plus ASO sequencing (Aligos), and therapeutic vaccines (Brii BRII-179). The combined week confirmed that liver disease is now a multi-mechanism therapeutic arena where peptides anchor the metabolic and entry-inhibitor lanes while gene and immune modalities pursue functional cure. ADA 2026 (June 5-8 New Orleans) is the next major readout window for the metabolic-peptide side.
The ASCO 2026 Annual Meeting opened today at McCormick Place Chicago, running through June 2, with more than 7,000 abstracts. The peptide-and-targeted-conjugate oncology cohort — pre-released in the May 21 abstract drop and the May 26 embargoed press briefing — now moves to live presentation. Friday May 29 brought the Corbus CRB-701 Nectin-4 ADC cervical/OPSCC data and the Dana-Farber/Bristol multiple myeloma and Pfizer lung cancer readouts. The peptide-mechanism slate across the meeting: Bicycle Therapeutics zelenectide pevedotin Duravelo-2 (bicyclic peptide-MMAE conjugate, oral June 1); Avacta AVA6000 FAP-Dox; BriaCell Bria-IMT cell-and-peptide immunotherapy; Sapience lucicebtide C/EBPβ antagonist (GBM); Aktis AKY-2519 B7-H3 miniprotein radioconjugate; Mayo TPIV200 folate-receptor peptide vaccine (TNBC, June 1); Telix ProstACT PSMA radioligand (June 1); plus the GLP-1 cancer slate (Abstract 3143, Roswell Park breast cancer). The targeted-conjugate categories — Nectin-4, PSMA, B7-H3, FAP, SSTR2 — are the densest peptide-adjacent oncology competition at the meeting.
EASL 2026 wraps in Barcelona Saturday May 30 after a week that confirmed MASH as a multi-mechanism therapeutic battleground. The GLP-1/glucagon peptide cohort delivered the headline data: Boehringer Ingelheim's survodutide full 48-week Phase 2 results in the NEJM (47-62% MASH improvement without fibrosis worsening, Phase 3 LIVERAGE enrolling); Altimmune's pemvidutide 48-week IMPACT data selected 'Best of EASL 2026' (triglycerides -23.7%, weight -7.5%, with HistoIndex qFibrosis fibrosis regression); MetaVia DA-1726 higher-dose Phase 1. The non-peptide cohort: Madrigal Rezdiffra eight-poster cardiovascular and portal-hypertension data, Aligos ALG-055009 THR-β (46.2% liver fat), Arrowhead ARO-INHBE RNAi (44% liver fat plus tirzepatide combination doubling weight loss), Galectin belapectin, Sagimet denifanstat. Novo Nordisk's ESSENCE Japanese and menopausal subgroups plus real-world burden data anchored the semaglutide MASH-labeling case. The week established that no single mechanism dominates MASH — GLP-1/glucagon leads on combined weight-plus-liver effect, THR-β and FGF21 lead on direct antifibrotic action, and combination therapy is the emerging 2027-2028 thesis.
EASL 2026's first two days clarified the MASH-therapeutics competitive map across five mechanism classes. GLP-1/glucagon dual peptides: Altimmune pemvidutide (48-week IMPACT data, Best of EASL), Boehringer survodutide (NEJM 47-62% MASH improvement, LIVERAGE Phase 3), MetaVia DA-1726 (48 mg Phase 1). THR-β agonists: Madrigal Rezdiffra (only FDA-approved MASH therapy, eight EASL posters), Aligos ALG-055009 (46.2% liver-fat reduction Phase 2a). RNAi: Arrowhead ARO-INHBE (Activin E/ALK7, 44% liver fat, tirzepatide combination). FASN inhibition: Sagimet denifanstat + Rezdiffra combination. FGF21 analogs: the Akero efruxifermin (Novo $5.2B acquisition) and 89bio pegozafermin (Roche $3.5B acquisition) programs anchoring the most-acquired MASH mechanism. Plus galectin-3 inhibition (Galectin belapectin NAVIGATE) and pan-PPAR agonism (Inventiva lanifibranor NATiV3 Phase 3). The GLP-1/glucagon peptide class leads on combined weight-loss-plus-liver effect; the FGF21 and THR-β classes lead on pure antifibrotic mechanism. Combination therapy across mechanism classes is the emerging 2026 thesis.
Novo Nordisk extended its EASL 2026 ESSENCE presentation cycle into Day 2 with real-world evidence quantifying the MASH disease burden — documenting significant quality-of-life impairment and escalating healthcare costs in MASH patients — alongside the Japanese MASH and menopausal women subgroup analyses presented Day 1. The data builds the health-economic case for semaglutide 2.4 mg following the August 2025 FDA MASH-with-fibrosis approval. MASH affects roughly 1 in 3 people living with overweight or obesity worldwide, with the majority undiagnosed. Novo's 'Love Your Liver' EASL initiative offered on-site MASH testing for attendees. The real-world burden data complements the ESSENCE Phase 3 efficacy story by establishing the economic and quality-of-life rationale for early MASH intervention — a payer-facing argument as the GLP-1 MASH indication scales into 2026-2027 against the THR-β, FGF21, and GLP-1/glucagon competitor classes.
The ASCO 2026 Annual Meeting opens tomorrow Friday May 29 at McCormick Place Chicago, running through June 2. The peptide-and-targeted-conjugate oncology slate that landed in the May 21 abstract release and the May 26 embargoed press briefing: Bicycle Therapeutics Duravelo-2 Phase 2 (zelenectide pevedotin 65% ORR / 58% BICR-confirmed in 1L urothelial, oral June 1 8:30 AM); Avacta AVA6000 FAP-Dox Phase 1a/1b in salivary gland (90% disease control); BriaCell Bria-IMT 16.6-month median OS in metastatic breast cancer; Sapience lucicebtide 28.4-month projected median PFS in glioblastoma; Corbus CRB-701 Nectin-4 ADC in HNSCC and cervical (oral May 29); Crinetics CRN09682 SSTR2 non-peptide drug conjugate BRAVESST2; Aktis AKY-2519 B7-H3 miniprotein radioconjugate; Mayo Clinic TPIV200 folate-receptor peptide vaccine in TNBC; plus the GLP-1 cancer slate (Abstract 3143, Roswell Park breast cancer). ASCO 2026 follows immediately after EASL 2026 closes May 30 — the back-to-back meeting structure makes the May 27-June 2 window the highest-density peptide-data week of 2026.
EASL 2026 Day 1 in Barcelona delivered the most concentrated MASH-therapeutics data cycle of 2026. The peptide-mechanism cohort: Altimmune pemvidutide qFibrosis fibrosis regression (LBP-036), MetaVia DA-1726 48 mg Phase 1 noninvasive liver assessment, Novo Nordisk ESSENCE Japanese/menopausal subgroups. The non-peptide-mechanism cohort: Arrowhead ARO-INHBE RNAi (Activin E/ALK7 pathway), Galectin Therapeutics belapectin NAVIGATE (galectin-3 inhibitor), Sagimet Biosciences denifanstat + resmetirom combination (FASN inhibitor + Madrigal's Rezdiffra), Madrigal eight-poster Rezdiffra data drop on cardiovascular and portal hypertension markers. The combined cycle reframes MASH as a multi-mechanism battleground rather than a single-class indication — GLP-1/glucagon peptides compete against thyroid-hormone-receptor agonism, RNAi, galectin-3 inhibition, FASN inhibition, and emerging combinations. Thursday May 28 brings the Altimmune pemvidutide oral presentation at 17:00 CEST; Friday May 29 brings ASCO opening in Chicago to anchor the parallel peptide-oncology cycle.
Oorja Bio launched as a clinical-stage company on May 19 with a $30M Series A from Westlake BioPartners and announced Phase 1 first-in-human clinical data for its lead asset ORJ-001 in idiopathic pulmonary fibrosis (IPF). ORJ-001 is a first-in-class subcutaneous peptide therapeutic — a selective β1 integrin agonist — designed to restore the function of alveolar epithelial type 2 (AEC2) cells, the lung cells that repair alveolar damage and lose regenerative capacity in IPF. Phase 1 in healthy volunteers showed therapeutically relevant exposure and favorable tolerability; in vitro target engagement in lung epithelial cells and fibroblasts ran in the nanomolar range matching achieved plasma concentrations. Preclinical bleomycin-induced lung fibrosis models documented reversal of established fibrosis and regeneration of normal alveolar morphology. The company has FDA IND clearance and plans Phase 2 initiation in IPF patients in 2026. The Houston-based biotech joins Animate Biosciences, Rein Therapeutics' LTI-03, and Avalyn Pharma as peptide-focused IPF programs.
ASCO holds its embargoed virtual press briefing for credentialed media today Tuesday May 26 from 3:30-5:00 PM ET. The briefing previews Late-Breaking Abstracts (LBAs) being presented Saturday May 30 at the Annual Meeting opening Friday May 29 in Chicago. LBA embargoes lift at 7:00 AM CT / 8:00 AM ET on the day of scientific presentation. Notable previewed material includes Abstract 3143 (the 12,112-patient real-world GLP-1 cancer metastasis analysis), the ARACOG (AFT-47) randomized clinical trial on cognitive effects of darolutamide vs enzalutamide, and additional peptide-oncology data from the previously-announced cohort. The May 26 briefing is the first formal media-access opportunity for LBA data and feeds directly into Wednesday-Thursday cycle press coverage that bridges into the meeting opening Friday.
Altimmune confirmed the IMPACT Phase 2b 48-week analysis on pemvidutide in MASH was selected as a 'Best of EASL 2026' abstract — the highest-tier curated designation at the European Association for the Study of the Liver Congress. The oral presentation is scheduled Thursday May 28 at 17:00 CEST in Barcelona, complementing the late-breaking fibrosis-regression poster Wednesday May 27 08:30 CEST. The 'Best of EASL' selection elevates pemvidutide relative to the broader MASH-peptide slate at the meeting (Novo Nordisk's ESSENCE semaglutide liver safety, Boehringer Ingelheim's survodutide SYNCHRONIZE-1 forward-look, Madrigal's Rezdiffra portal hypertension data) and is the meeting committee's editorial signal that the IMPACT Phase 2b data set is among the highest-impact contributions to the congress.
Zealand Pharma A/S held its Extraordinary General Meeting at Plesner Advokatpartnerselskab in Copenhagen on May 26, 2026. All proposals presented were approved, with Camilla Sylvest elected to the Board of Directors as recommended by the Nomination Committee. No other shareholder-elected board composition changes were proposed. Zealand's 2026 pipeline anchors on three programs: petrelintide (ZP8396, amylin analog under a $5.3B March 2026 Roche partnership), survodutide (BI 456906, dual GLP-1/glucagon agonist partnered with Boehringer Ingelheim, SYNCHRONIZE-1 obesity Phase 3 readout April 2026 documenting 16.6% weight loss), and the next-generation amylin and glucagon programs. The corporate-governance update is routine; the strategic story remains the SYNCHRONIZE-MASH Phase 3 readout expected late 2026, which positions survodutide as a leading candidate for the dual GLP-1/glucagon agonist class in MASH alongside pemvidutide.